MX2021006026A - Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos. - Google Patents

Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.

Info

Publication number
MX2021006026A
MX2021006026A MX2021006026A MX2021006026A MX2021006026A MX 2021006026 A MX2021006026 A MX 2021006026A MX 2021006026 A MX2021006026 A MX 2021006026A MX 2021006026 A MX2021006026 A MX 2021006026A MX 2021006026 A MX2021006026 A MX 2021006026A
Authority
MX
Mexico
Prior art keywords
pyrimidine
preparation
membered nitrogen
nitrogen heterocycle
method therefor
Prior art date
Application number
MX2021006026A
Other languages
English (en)
Inventor
Wei Zhu
Jian Yu
Zhengtao Li
Hao Zou
Yuanhao Wang
Original Assignee
Tuojie Biotech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuojie Biotech Shanghai Co Ltd filed Critical Tuojie Biotech Shanghai Co Ltd
Publication of MX2021006026A publication Critical patent/MX2021006026A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención se refiere a una pirimidina y un derivado heterocíclico de nitrógeno de cinco miembros, un método de preparación para la misma y los usos médicos de los mismos. En particular, la presente invención se refiere a una pirimidina y un derivado heterocíclico de nitrógeno de cinco miembros representado por la fórmula general (I), un método de preparación de la misma, una composición farmacéutica que contiene el derivado y los usos de la misma como inhibidor de SHP2 para su uso en la prevención y/o tratamiento de tumores o cáncer, en donde cada sustituyente en la fórmula general (I) es como se define en la descripción.
MX2021006026A 2018-11-30 2019-11-29 Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos. MX2021006026A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811452514 2018-11-30
CN201910577816 2019-06-28
PCT/CN2019/121844 WO2020108590A1 (zh) 2018-11-30 2019-11-29 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2021006026A true MX2021006026A (es) 2021-07-06

Family

ID=70852404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006026A MX2021006026A (es) 2018-11-30 2019-11-29 Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.

Country Status (11)

Country Link
EP (1) EP3889153A4 (es)
JP (1) JP2022509149A (es)
KR (1) KR20210097144A (es)
CN (1) CN113272303A (es)
AU (1) AU2019386036A1 (es)
BR (1) BR112021009880A2 (es)
CA (1) CA3120791A1 (es)
MX (1) MX2021006026A (es)
TW (1) TW202039498A (es)
WO (1) WO2020108590A1 (es)
ZA (1) ZA202102728B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
EP3694848A1 (en) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
EP3724189B1 (en) 2017-12-15 2023-10-04 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
WO2019158019A1 (zh) 2018-02-13 2019-08-22 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
CN110156786B (zh) * 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 嘧啶并环化合物及其制备方法和应用
CN111138412B (zh) 2018-11-06 2023-09-15 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
US20220127271A1 (en) * 2018-11-07 2022-04-28 Shanghai Ringene Biopharma Co., Ltd. Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
WO2021088945A1 (zh) * 2019-11-08 2021-05-14 南京圣和药业股份有限公司 作为shp2抑制剂的化合物及其应用
CN113754683A (zh) * 2020-06-05 2021-12-07 上海奕拓医药科技有限责任公司 同位素取代的螺芳环化合物及其应用
WO2021254449A1 (zh) * 2020-06-18 2021-12-23 上海奕拓医药科技有限责任公司 一种shp2抑制剂的晶型及其组合物、制备方法和用途
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
CN112402385B (zh) * 2020-11-30 2022-04-01 北京华氏开元医药科技有限公司 4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法
CN112194652B (zh) * 2020-11-30 2021-03-05 北京华氏开元医药科技有限公司 4-羟甲基-1h-吲哚类化合物、制备方法及应用
WO2022135568A1 (zh) * 2020-12-25 2022-06-30 江苏恒瑞医药股份有限公司 一种嘧啶并五元氮杂环类衍生物的晶型及其制备方法
PE20240634A1 (es) * 2021-02-05 2024-03-26 Hutchmed Ltd Compuestos triciclicos y usos de los mismos
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
KR20240004960A (ko) 2021-05-05 2024-01-11 레볼루션 메디슨즈, 인크. Ras 억제제
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
WO2022241975A1 (en) * 2021-05-20 2022-11-24 Etern Biopharma (Shanghai) Co., Ltd. Methods for treating cancers associated with egfr mutation
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
TW202328133A (zh) * 2021-08-27 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Shp2抑制劑治療含有ras通路基因突變的腫瘤的用途
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN114213417B (zh) * 2021-11-16 2023-08-22 郑州大学 吡唑并六元氮杂环类化合物及其合成方法和应用
CN116514844A (zh) * 2022-01-20 2023-08-01 思路迪生物医药(上海)有限公司 一类噻吩并嘧啶类衍生物及其作为泛kras突变抑制剂的用途
EP4227307A1 (en) * 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023230968A1 (zh) * 2022-06-01 2023-12-07 上海凌达生物医药有限公司 Shp2抑制剂、其晶型及其制备方法与用途
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2131790A1 (de) * 1971-06-26 1973-01-11 Bayer Ag N-substituierte-n'-pyrazolo eckige klammer auf 1,5-c eckige klammer zu pyrimidin-amidine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB0301350D0 (en) * 2003-01-21 2003-02-19 Merck Sharp & Dohme Therapeutic agents
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
CA2953482A1 (en) 2013-07-03 2015-01-08 Indiana University Research & Technology Corporation Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JP6631616B2 (ja) * 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
SG11201703880VA (en) * 2014-12-23 2017-07-28 Novartis Ag Triazolopyrimidine compounds and uses thereof
TWI714567B (zh) * 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
AU2016255431B2 (en) * 2015-04-29 2020-05-07 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CN112625028A (zh) 2015-06-19 2021-04-09 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
EP4108659A1 (en) 2016-06-07 2022-12-28 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
CN116478132A (zh) 2016-07-12 2023-07-25 锐新医药公司 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪
TW201819386A (zh) 2016-10-24 2018-06-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
AU2018207464B2 (en) 2017-01-10 2020-05-14 Novartis Ag Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
US11117899B2 (en) * 2017-04-07 2021-09-14 Medshine Discovery Inc. [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor
EP3724189B1 (en) * 2017-12-15 2023-10-04 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CA3089639A1 (en) * 2018-01-31 2019-08-08 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidinyl compounds as prc2 inhibitors
CN110156786B (zh) * 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 嘧啶并环化合物及其制备方法和应用
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN112384515A (zh) * 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和***并嘧啶
CN111138412B (zh) * 2018-11-06 2023-09-15 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用

Also Published As

Publication number Publication date
CN113272303A (zh) 2021-08-17
ZA202102728B (en) 2022-09-28
TW202039498A (zh) 2020-11-01
WO2020108590A1 (zh) 2020-06-04
CA3120791A1 (en) 2020-06-04
JP2022509149A (ja) 2022-01-20
EP3889153A4 (en) 2022-09-07
BR112021009880A2 (pt) 2021-08-17
EP3889153A1 (en) 2021-10-06
KR20210097144A (ko) 2021-08-06
AU2019386036A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
PH12020551305A1 (en) Pharmaceutical Compounds
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
MX2022001908A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina.
CR20220363A (es) Compuestos tricíclicos sustituidos
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CR20220312A (es) Compuestos tricíclicos sustituidos
MX2018002889A (es) Compuesto de pirimidina fusionada o sal del mismo.
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
MX2021003655A (es) Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina.
GEP20166484B (en) Protein kinase inhibitors
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
AU2024202525A1 (en) Benzimidazolone derived inhibitors of BCL6
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer